**S5 Fig. Predictive ability of OPN for CDAI remission in patients with RA who received TCZ with concomitant MTX**

(A) Logistic regression analysis showing association of increasing baseline osteopontin (OPN) levels with decreasing predicted probability of achieving Clinical Disease Activity Index (CDAI) remission at 1 year. (B) ROC curve showing a cut-off baseline OPN level of 17.3 ng/mL, discriminating between CDAI remission and non-remission at 1 year, with a sensitivity of 58% and a specificity of 81%.

****